Sector News

Think Allergan CEO’s ‘all-consuming’ Valeant fight won’t happen to you? Think again

February 10, 2015
Life sciences
Fending off a hostile bid last year from partners Valeant ($VRX) and activist investor Bill Ackman wasn’t just a lot of work, according to Allergan CEO David Pyott. It was a full-time job.
 
Pyott Tuesday called the months-long process “all-consuming” on CNBC’s “Squawk Box,” recounting how he tasked President Doug Ingram and Chief Science Officer Scott Whitcup with handling day-to-day operations while he focused his own efforts on the takeover battle.
 
“‘I will concentrate on the raiders, investors, public relations, all of the above,'” he said, recalling what he’d told them after the first Valeant-Ackman bid hit in late April.
 
Ultimately, his efforts paid off, with Allergan successfully fending off its hostile suitors long enough to arrange a $66 billion merger with white knight Actavis. Pyott says the team “constantly ramped up” its performance, too, accounting for part of the $20 billion stock increase since Valeant’s first offer.
 
Pyott may serve as an example for pharma’s embattled CEOs of the future–and the way EY’s analysts see it, at least some of the industry’s execs will find themselves in similar positions. “Shareholder activism is on the rise,” the analysts wrote in a recent report, saying they expect it to be one of the key factors affecting M&A this year.
 
Even execs who aren’t in the middle of a trench war–the way Pyott was–will have to devote more of their time to shoring up their defenses, report author Jeff Greene told FiercePharma in January. “You’ll see boards and senior management teams giving analysts more respect and trying to get out in front of investors and preempt” the Ackmans out there, he said. “They’ll “take their own actions to maximize shareholder value before activists can get involved.”
 
By Carly Helfand  
 

comments closed

Related News

July 3, 2022

Novo Nordisk joins with nursing group to highlight correlation between Type 2 diabetes and cardio risk

Life sciences

Despite atherosclerotic cardiovascular disease (ASCVD) being the leading cause of death for people with Type 2 diabetes, half of those people have no idea of this risk. Novo Nordisk has teamed up with the Preventive Cardiovascular Nurses Association (PCNA) for “Making the Connection,” a program to help increase understanding of the link between the two diseases.

July 3, 2022

First treatment for ‘broken heart syndrome’ trialled

Life sciences

The first ever treatment for broken heart syndrome – also known as Takotsubo cardiomyopathy – is to be trialled by researchers at the University of Aberdeen. Scientists will trial a programme of exercise conditioning and psychological therapy for people who have been diagnosed with the condition following a £300,000 grant from the British Heart Foundation.

July 3, 2022

Nestlé acquiring The Better Health Company in market expansion deal

Life sciences

Nestlé Health Science is set to acquire The Better Health Company (TBHC), as part of its goals to grow global market share while spurring innovation across the nutrition industry. The acquisition includes the GO Healthy brand with its vitamins and supplements, Egmont, the Manuka honey brand and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins minerals and supplements.